Fipaxalparant clinical trials

A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

This study is looking at a new medicine called Fipaxalparant for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It's a second-stage trial to see how well it works and if it's safe over about a year.